The main endocannabinoid receptor subtype , the CB1 receptor , is widely distributed in the brain. Rimonabant is a CB1 cannabinoid receptor antagonist which has been shown in animals to reduce alcohol consumption. This protocol is intended to determine if Rimonabant will decrease alcohol consumption in individuals who consume between 20 and 50 drinks of alcohol per week. Enrollment for the study has been completed and the data is in the process of being analyzed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Intramural Research (Z01)
Project #
1Z01AA000208-04
Application #
7317714
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
United States
Zip Code